

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
26 May 2005 (26.05.2005)

PCT

(10) International Publication Number  
**WO 2005/047336 A1**

(51) International Patent Classification<sup>7</sup>: **C07K 19/00**

143-210 (KR). LEE, Gwan, Sun [KR/KR]; #3-404, Woochang Apt., Ogeum-dong, Songpa-gu, Seoul 138-739 (KR).

(21) International Application Number:  
PCT/KR2004/002944

(74) Agent: SON, Min; 19th Floor, City Air Tower, 159-9 Samsung-dong, Gangnam-gu, Seoul 135-973 (KR).

(22) International Filing Date:  
13 November 2004 (13.11.2004)

(25) Filing Language: Korean

(26) Publication Language: English

(30) Priority Data:  
10-2003-0080299  
13 November 2003 (13.11.2003) KR

(71) Applicant (for all designated States except US): HANMI PHARM. IND. CO., LTD. [KR/KR]; #893-5, Hajeo-ri, Paltan-myeon, Hwaseong-si, Gyeonggi-do 445-813 (KR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): KIM, Young, Min [KR/KR]; #102-803, Woonam dreamvalley, Gomae-ri, Giheung-eup, Yongi-si, Gyeonggi-do 449-901 (KR). KIM, Dae, Jin [KR/KR]; #28-402, Gubampo Apt., Banpobon-dong, Seocho-gu, Seoul 137-049 (KR). BAE, Sung, Min [KR/KR]; #1360-24 (401), Seocho2-dong, Seocho-gu, Seoul 137-072 (KR). LIM, Chang, Ki [KR/KR]; #325-1706, Samic Apt., Yeongtong-dong, Yeongtong-gu, Suwon-si, Gyeonggi-do 443-470 (KR). KWON, Se, Chang [KR/KR]; #1002-2103, Hyundai 10-cha Apt., Gwangjang-dong, Gwangjin-gu, Seoul

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROTEIN COMPLEX USING IMMUNOGLOBULIN FRAGMENT ANDMETHOD FOR THE PREPARATION THEREOF



(57) Abstract: Disclosed are a protein conjugate with improved *in vivo* duration and stability and the use thereof. The protein conjugate includes a physiologically active polypeptide, a non-peptide polymer and an immunoglobulin Fc fragment. Since the three components are covalently linked, the protein conjugate has extended *in vivo* duration and enhanced stability for the physiologically active polypeptide. The protein conjugate maintains the *in vivo* activity at relatively high levels and remarkably increases the serum half-life for the physiologically active polypeptide, with less risk of inducing undesirable immune responses. Thus, the protein conjugate is useful for developing long-acting formulations of various polypeptide drugs.